SEC Company Response from FILANA THERAPEUTICS, (FLNA) — Apr 9, 2020
FILANA THERAPEUTICS, INC.
Date: April 9, 2020 · CIK: 0001069530 · Accession: 0001069530-20-000026
AI Filing Summary & Sentiment
File numbers found in text: 333-237452
Referenced dates: April 2, 2020
Letter
Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission 100 F Street, N.E. Mail Stop 3030 Washington, D.C. 20549 Re: Cassava Sciences, Inc. Registration Statement on Form S-3 Filed March 27, 2020 File No. 333-237452
Dear Mr. Jeffrey Gabor:
On behalf of Cassava Sciences, Inc. (the “Company”), we submit this letter providing responses to the comments raised by the Staff of the Securities and Exchange Commission (the “Staff”) in its letter dated April 2, 2020, with respect to the registration statement on Form S-3 (File No. 333-237452), as amended (the “Registration Statement”).
Below we have noted the Staff’s comments in bold face type and the Company’s responses in regular type.
Units
1.If you plan to offer units, please revise the registration statement fee table and prospectus cover page to identify the units as securities in the offering, identifying the components of the units. Please also include disclosure regarding the units you are registering.
Jeffrey Gabor
April 9, 2020
Page 2
Response: In response to the Staff’s comment, we have filed an S-3/A revising the registration statement fee table and prospectus cover page. We have also included disclosure regarding the units in the prospectus.
Legality Opinion
2.Your legality opinion should address the legality of the depositary shares being offered.
Response: In response to the Staff’s comment, we have filed a new opinion as Exhibit 5.1 which addresses the legality of depositary shares being offered.
Jeffrey Gabor
April 9, 2020
Page 3
We appreciate your time and attention to this Amendment No. 1, as well as to the Company’s responses to the Staff’s comments. Should you have any additional questions or concerns, please call me at (415) 268-6213.
Sincerely,
Show Raw Text
CORRESP 1 filename1.htm S-3A -Cassava SEC Response Letter 415.268.7000 Facsimile: 415.268.7522 boston, brussels, denver, hong kong, london, los angeles, new york, northern virginia, palo alto, san diego, san francisco, shanghai, singapore, tokyo, washington, d.c. 425 Market Street San Francisco California 94105-2482 Telephone: 415.268.7000 Facsimile: 415.268.7522 www.mofo.com morrison & foerster llp beijing, berlin, boston, brussels, denver, hong kong, london, los angeles, new york, northern virginia, palo alto, san diego, san francisco, shanghai, singapore, tokyo, washington, d.c. April 9, 2020 Jeffrey Gabor Attorney Advisor Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission 100 F Street, N.E. Mail Stop 3030 Washington, D.C. 20549 Re: Cassava Sciences, Inc. Registration Statement on Form S-3 Filed March 27, 2020 File No. 333-237452 Dear Mr. Jeffrey Gabor: On behalf of Cassava Sciences, Inc. (the “Company”), we submit this letter providing responses to the comments raised by the Staff of the Securities and Exchange Commission (the “Staff”) in its letter dated April 2, 2020, with respect to the registration statement on Form S-3 (File No. 333-237452), as amended (the “Registration Statement”). Below we have noted the Staff’s comments in bold face type and the Company’s responses in regular type. Units 1.If you plan to offer units, please revise the registration statement fee table and prospectus cover page to identify the units as securities in the offering, identifying the components of the units. Please also include disclosure regarding the units you are registering. Jeffrey Gabor April 9, 2020 Page 2 Response: In response to the Staff’s comment, we have filed an S-3/A revising the registration statement fee table and prospectus cover page. We have also included disclosure regarding the units in the prospectus. Legality Opinion 2.Your legality opinion should address the legality of the depositary shares being offered. Response: In response to the Staff’s comment, we have filed a new opinion as Exhibit 5.1 which addresses the legality of depositary shares being offered. Jeffrey Gabor April 9, 2020 Page 3 We appreciate your time and attention to this Amendment No. 1, as well as to the Company’s responses to the Staff’s comments. Should you have any additional questions or concerns, please call me at (415) 268-6213. Sincerely, /s/ Alfredo B.D. Silva Alfredo B.D. Silva cc: Celeste Murphy (Division of Corporate Finance) Eric J. Schoen (Cassava Sciences, Inc.)